Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × Neoplasms × olaparib × Clear all

Status

Completed 9 Recruiting 7 Unknown 3 Terminated 2 Withdrawn 1 Approved for marketing 1 Active not recruiting 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 1 Ovarian Diseases 1 Neoplasms 1 Carcinoma, Ovarian Epithelial 1

Interventions

vorasidenib 1 tovorafenib 1 olaparib 1 glucarpidase 1 enzalutamide 1 adagrasib 1 Nivolumab 1 Carboxypeptidases 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03079687 2017-10-25

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

AstraZeneca

Approved for marketing

Carcinoma, Ovarian Epithelial, Neoplasms, Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡